Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Quantitative and qualitative visual outcomes of refined single-step transepithelial photorefractive keratectomy in hyperopia: 18-month follow-up study

Poster Details

First Author: S.Adib-Moghaddam IRAN

Co Author(s): S. Soleyman-Jahi   G. Tefagh   M. Razi   A. Haydar           

Abstract Details


To evaluate visual outcomes after refined single-step Transepithelial Photorefractive Keratectomy (TransPRK) in hyperopic eyes. This is the longest follow-up and the first report of how this method affects contrast sensitivity (CS) in hyperopic eyes.


Bina Eye Hospital, Tehran, Iran


Thirty-nine eyes (23 patients) with hyperopia (0.5-5.5 D) with or without astigmatism (0.25-4.75 D) were recruited in an 18-month follow-up study. All of the cases underwent aberration-free mode Refined Single-step Trans-PRK by the same expert refractive surgeon (S.A.M.) using SCHWIND AMARIS 500 laser. Mean age was 36.36±11.62 and 22 eyes (56.41%) belonged to female patients. Mean preoperative spherical equivalent, logMAR UDVA and CDVA were 3.11±1.4 D, 0.25±0.37 and 0.13±0.25, respectively.


By 18 months post-operatively, spherical equivalent, logMAR UDVA, and CDVA improved to 0.10±0.32 (P<0.001), -0.04±0.08 (P=0.001), and -0.05±0.08 (P=0.006). Efficacy and safety indices were 1.50±0.80 and 1.52±0.79, respectively. Number of eyes with postoperative UDVA equal or above 20/25 and 20/20 were 100 and 76.5%, respectively. The rates for ±0.5D and ±1.0D predictabilities were 94.12 and 97.10%, respectively. Photopic and Mesopic contrast sensitivity function showed no significant change (1.06 to 1.22 [P=0.06] and 1.20 to 1.30 [P = 0.2], respectively).


This study showed that refined single-step TransPRK was effective procedure in treatment of hyperopic eyes to improve visual acuity and refraction. It did not significantly and clinically deteriorate contrast sensitivity.

Financial Disclosure:


Back to Poster listing